HC Wainwright Issues Pessimistic Estimate for ALDX Earnings

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) – Equities research analysts at HC Wainwright decreased their FY2027 earnings estimates for shares of Aldeyra Therapeutics in a research note issued on Wednesday, March 4th. HC Wainwright analyst M. Caufield now expects that the biotechnology company will earn $0.08 per share for the year, down from their prior estimate of $0.11. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03.

Separately, BTIG Research reissued a “buy” rating and issued a $9.00 price target on shares of Aldeyra Therapeutics in a report on Monday, November 10th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Aldeyra Therapeutics currently has a consensus rating of “Hold” and an average price target of $9.50.

Aldeyra Therapeutics Stock Down 5.8%

Shares of Aldeyra Therapeutics stock traded down $0.30 during trading on Thursday, hitting $4.90. 458,937 shares of the company were exchanged, compared to its average volume of 806,765. The firm has a 50 day moving average price of $5.03 and a 200 day moving average price of $5.17. The stock has a market capitalization of $294.88 million, a price-to-earnings ratio of -8.60 and a beta of 0.97. Aldeyra Therapeutics has a fifty-two week low of $1.14 and a fifty-two week high of $7.20.

Institutional Investors Weigh In On Aldeyra Therapeutics

Several hedge funds have recently made changes to their positions in the business. AQR Capital Management LLC lifted its position in Aldeyra Therapeutics by 275.4% during the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company’s stock valued at $5,645,000 after buying an additional 1,081,257 shares in the last quarter. 683 Capital Management LLC raised its stake in shares of Aldeyra Therapeutics by 86.6% in the 4th quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company’s stock valued at $7,925,000 after acquiring an additional 710,000 shares during the period. Kennedy Capital Management LLC lifted its holdings in shares of Aldeyra Therapeutics by 61.9% during the 3rd quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company’s stock valued at $5,806,000 after acquiring an additional 425,245 shares in the last quarter. Bank of America Corp DE boosted its position in Aldeyra Therapeutics by 590.5% during the 3rd quarter. Bank of America Corp DE now owns 390,078 shares of the biotechnology company’s stock worth $2,036,000 after purchasing an additional 333,587 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its position in Aldeyra Therapeutics by 49.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 947,551 shares of the biotechnology company’s stock worth $4,946,000 after purchasing an additional 313,395 shares during the period. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.